Sovereign Capital Partners-backed Bioscript Group has acquired Triducive Partners, a consultancy specializing in clinical opinion development for pharmaceutical and life sciences companies. The deal marks the fifth acquisition Bioscript has completed since Sovereign invested in the business in 2021.

Triducive works with major pharmaceutical clients including AstraZeneca and Johnson & Johnson, helping these companies gather and publish clinical opinion. The acquisition strengthens Bioscript's ability to support clients across the full medical affairs value chain, from drug development through commercialization.

The deal continues Bioscript's aggressive expansion strategy under Sovereign's ownership. By adding Triducive's specialized capabilities in medical communications and clinical evidence generation, Bioscript positions itself as a comprehensive partner for pharmaceutical companies seeking end-to-end medical affairs support.